Sakar Healthcare of India manufactures a growing range of pharmaceutical formulations for both domestic and international markets. SAKAR has already proven a decade-long operational success in supplying diversified range of pharmaceutical products for premier multinational corporations for their domestic and overseas operations. Sakar Healthcare maintains a global network of distributors and has obtained brand in most major markets. It is currently in the process of expanding globally, foraying into regulated markets including European Union, looking out for overseas Strategic Joint ventures and Market acquisitions.
Seizing the moment, Sakar Healthcare debuted on the small and medium-sized enterprise (SME) board of India’s National Stock Exchange (NSE) in September. The IPO raised funds to build a new lyophilisation facility, bolster working capital reserves, and finance registration processes abroad, amongst others. The company is also working on plans to market pharmaceuticals under its own brand name, potentially lifting the business bottom line.
Sakar Healthcare has established an enviable reputation for quality control enabling the company to broach new markets and quickly gain regulatory approval for its products. With state-of-the-art and fully-automated manufacturing facilities equipped with machines imported from Germany, Italy, Switzerland and a comprehensive product line, Sakar Healthcare is poised for sustained organic growth, leveraging its core competency.
The CFI.co judging panel notes that the company has expended considerable efforts at providing world-class pharmaceutical formulations and maintaining benchmark-setting quality levels attained by the continuous monitoring of its output. The judges also remarked that the company has timed its IPO to coincide with strong investor demand for shares in tech-heavy medium-sized businesses that are set for a breakout. The judges are pleased to offer Sakar Healthcare the 2016 Best SME Growth IPO India Award.